Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $17.25.

ENTA has been the topic of a number of analyst reports. HC Wainwright reduced their price target on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, December 24th. JMP Securities reiterated a “market outperform” rating and issued a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Finally, Robert W. Baird lowered their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, November 26th.

Insider Buying and Selling

In related news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.06, for a total transaction of $41,444.52. Following the transaction, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. This represents a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.64% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers boosted its position in shares of Enanta Pharmaceuticals by 4.7% during the 2nd quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock worth $448,000 after purchasing an additional 1,548 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Enanta Pharmaceuticals in the second quarter worth approximately $35,000. US Bancorp DE grew its stake in Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 4,243 shares during the period. American Century Companies Inc. increased its holdings in shares of Enanta Pharmaceuticals by 35.4% during the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after acquiring an additional 7,287 shares in the last quarter. Finally, Quest Partners LLC raised its position in shares of Enanta Pharmaceuticals by 65.0% during the third quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 7,535 shares during the period. 94.99% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA opened at $5.85 on Thursday. Enanta Pharmaceuticals has a 52 week low of $5.70 and a 52 week high of $17.80. The stock has a market capitalization of $123.98 million, a price-to-earnings ratio of -1.07 and a beta of 0.49. The stock has a fifty day moving average of $9.01 and a 200-day moving average of $11.41.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The business had revenue of $14.60 million for the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company’s revenue was down 22.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.33) earnings per share. As a group, equities analysts forecast that Enanta Pharmaceuticals will post -4.73 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.